CONSENSUS RECOMMENDATION The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain recommends against opioids for chronic pain management, emphasizing non-pharmacologic and non-opioid pharmacologic therapies. When opioids are used, the CDC recommends the lowest effective dosage for the shortest duration necessary.
Benefits:
Opioids are associated with no demonstrated benefit in ankle OA specifically. Theoretical short-term pain relief is possible, though the magnitude of benefit versus non-opioid analgesics is unclear and likely minimal based on general OA literature.
Harms:
Extensive and well-documented harms include addiction/dependence risk, overdose mortality risk, tolerance and dose escalation, opioid-induced hyperalgesia, constipation, nausea/vomiting, sedation and cognitive impairment, increased fall and fracture risk, respiratory depression, immunosuppression, and potential for diversion/misuse. Chronic opioid use is associated with worse functional outcomes in musculoskeletal conditions.
Outcome Importance:
Pain relief and functional improvement are critical for ankle osteoarthritis (OA) patients. However, opioids provide only symptomatic masking without addressing underlying pathology. The risk-benefit ratio is unfavorable given well-documented harms, lack of disease-modifying effects, and availability of alternative treatments.
Cost Effectiveness/Resource Utilization:
Opioids are relatively inexpensive medications ($10-100/month depending on formulation). However, true costs include monitoring requirements (prescription drug monitoring program checks, urine drug screens, frequent follow-up visits), management of side effects and complications, treatment of opioid use disorder when it develops, overdose events and emergency department visits, and societal costs of the opioid epidemic.
Acceptability:
Patient perspectives vary. Some patients request opioids for pain relief, influenced by prior prescribing practices and direct-to-consumer pharmaceutical marketing. However, increasing public awareness of opioid risks and the epidemic has shifted attitudes. From provider perspective, growing recognition of opioid harms, regulatory scrutiny, liability concerns, and professional guidelines have reduced willingness to prescribe opioids for chronic non-cancer pain.
Feasibility:
The recommendation against opioids is highly feasible given availability of multiple alternative treatments. Barriers to alternatives should be addressed rather than defaulting to opioids.
Future Research:
While the workgroup recommends against opioids based on known harms and lack of evidence, potential research questions include:
- Epidemiologic studies: What is the current prevalence of opioid prescribing for ankle OA? Has prescribing changed over time in response to guidelines and the epidemic?
- Comparative effectiveness: For patients with ankle OA already on opioids, what are outcomes of opioid tapering/discontinuation versus continuation? Does tapering improve or worsen function?
- Alternative analgesics: What is the comparative effectiveness of non-opioid analgesics (NSAIDs, acetaminophen, topical agents, gabapentinoids) versus placebo specifically for ankle OA?
- Multimodal pain management: What multimodal approaches (physical therapy + NSAIDs + injections + psychological support) provide optimal pain control without opioids?